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ABSTRACT
Standard assays used for influenza serology present certain practical issues, such as inter-laboratory variability, 
complex protocols and the necessity for handling certain virus strains in high biological containment facilities. 
In an attempt to address this, avian and human influenza HA pseudotyped retroviruses have been successfully 
employed in antibody neutralization assays. In this study we generated an equine influenza pseudotyped lentivi-
rus for serological screening. This was achieved by co-transfection of HEK293T cells with plasmids expressing 
the haemagglutinin (HA) protein of an H3N8 subtype equine influenza virus strain, HIV  gag-pol and firefly lucif-
erase reporter genes and harvesting virus from supernatant. In order to produce infective  pseudotype  particles 
it was necessary to additionally co-transfect a plasmid encoding the TMPRSS2 endoprotease to cleave the HA. 
High titre pseudotype virus (PV) was then used in PV antibody neutralization assays (PVNAs) to successfully 
distinguish between vaccinated and non-vaccinated equines. The sera were also screened by single radial hae-
molysis (SRH) assay. There was a 65% correlation between the results of the two assays, with the PVNA assay 
appearing slightly more sensitive. Future work will extend the testing of the PVNA with a larger number of 
serum samples to assess sensitivity/specificity, inter/intra-laboratory variability and to define a protective titre.
KEYWORDS: Influenza, pseudotype virus, viral screening, neutralizing antibody, H3N8, SRH, TMPRSS2
INTRODUCTION
Influenza infections in equine species are relatively com-
mon and can have significant economic impact. The primary 
clinical manifestation is acute respiratory disease. To date, 
infections have only been associated with two subtypes; 
H3N8 and H7N7. There have been no isolations of H7N7 
virus from horses for over 30 years (Webster, 1993), but 
viruses of the H3N8 subtype continue to cause outbreaks 
regularly across the globe, some affecting large numbers of 
animals (reviewed in Daly et al, 2011).
Equine influenza infection induces neutralising antibodies 
against the surface glycoproteins haemagglutinin (HA) and 
neuraminidase (NA). This is the primary protective immune 
response elicited by natural infection or vaccination, with cell-
mediated immunity playing a role in  clearing  virus-infected 
cells following natural infection (Paillot et al, 2006). As for 
human influenza, measurement of antibodies against the HA 
in particular is important in studies to determine vaccine 
efficacy (i.e., performance in experimental vaccination and 
challenge studies) and effectiveness (i.e., how well a vaccine 
performs when used routinely ‘in the field’).
The haemagglutination inhibition (HI) test is useful for virus 
characterisation and diagnostic purposes as it is a strain- 
specific assay. However, high levels of inter- laboratory vari-
ation are observed, as a result of which protective antibody 
levels are ill-defined, ranging from titres of 8 to 128 ( Mumford 
and Wood, 1992). For equine influenza, the requirement to 
treat the virus with Tween 80 and ether to improve the sensi-
tivity of the assay (John and Fulgitini, 1966) further increases 
 variability of the assay. The HI test only measures inhibition of 
HA binding to cells (HA globular head reactive  antibodies). 
305
©The Authors | Journal of Molecular and Genetic Medicine | 2012 | Vol 6 | 304-308 | OPEN ACCESS
The single radial haemolysis (SRH) assay measures 
 complement-mediated haemolysis induced by influenza 
antibody–antigen complexes. The SRH test can be stand-
ardised using reference sera (Daly et al, 2007) and a clear 
relationship has been demonstrated between pre-challenge 
antibody levels measured by SRH and protection afforded 
in challenge studies (Mumford and Wood, 1992). However, 
the SRH assay has disadvantages; it is relatively cumber-
some to perform; requires the use of sheep blood and guinea 
pig complement; and resulting zones of haemolysis have to 
be measured either using specialised equipment or by hand 
using digital callipers.
Measurement of virus neutralising (VN) antibodies against 
equine influenza is rarely performed; VN assays in eggs 
are time-consuming, labour-intensive and the lack of cyto-
pathic effect in cells often requires a two-step assay in which 
reduction in virus replication is measured by detection of 
viral protein by ELISA or other assays.
The use of equine influenza pseudotyped lentiviruses may 
provide a solution to the requirement for a reliable and repro-
ducible assay to assess the level of neutralising antibodies to 
equine influenza in vaccinated or naturally-infected horses. 
A number of avian and human influenza virus subtypes 
have been pseudotyped and used in such serological assays 
( Temperton et al, 2007; Temperton and Wright, 2009; Corti 
et al, 2011; Garcia and Lai, 2011). A pseudotype virus has 
the ‘core’ of one virus (e.g., a retrovirus) and the outer ‘enve-
lope’ protein of another (e.g., the HA of influenza virus). The 
core virus has deletions in the genome making it replication-
deficient, and harbours a reporter transgene (e.g., luciferase). 
The envelope glycoprotein permits entry into susceptible tar-
get cells. During cell transduction, the pseudotype virus (PV) 
genome becomes integrated in the cell genome and expresses 
the reporter gene. Thus the number of transduced cells can be 
quantified and the subsequent inhibitory effects of antibodies 
in serum on PV entry determined (Temperton et al, 2007; 
Temperton and Wright, 2009; Garcia and Lai, 2011).
The aim of the current study was to develop a pseudotype 
virus neutralization assay (PVNA) for the measurement of 
neutralising antibodies to H3N8 subtype equine influenza 
viruses.
MATERIALS AND METHODS
Viruses and sera
Stocks of A/equine/Sussex/89 (H3N8) influenza virus 
(a European lineage strain; Daly et al, 1996) were grown 
in 10-day-old embryonated hens’ eggs. Serum samples 
 surplus to diagnostic requirements were obtained from 20 
routinely influenza-vaccinated donkeys. The donkeys were 
recently (within 80 days) vaccinated with a booster dose of 
a commercially available inactivated vaccine containing the 
 American-lineage H3N8 strain A/equine/Newmarket/1/93, 
the European-lineage H3N8 strain A/equine/Newmar-
ket/2/93 in addition to A/equine/Prague/56 (H7N7). The 
epitope-bearing HA1 regions of the Sussex/89 and Newmar-
ket/93 viruses share 99% amino acid identity (as determined 
using CLUSTAL software). A batch of serum from a hyper- 
immunised experimental pony vaccinated with a number 
of H3N8 strains over two decades (A/equine/Suffolk/89, 
A/equine/Newmarket/1/93, A/equine/Newmarket/2/93, A/
equine/Ohio/03), was used as a positive control. Serum 
samples from two horses, confirmed to be influenza-naïve 
by SRH, were kindly provided by Prof. Ann Cullinane, Irish 
Equine Centre. Sera were stored at -80°C until use.
Generation of H3 pseudotyped virus
Viral RNA was extracted from allantoic fluid using the QIAmp 
viral RNA extraction kit (Qiagen). The full haemagglutinin 
gene was amplified by Titan One Tube RT-PCR (Roche) using 
custom primers (Invitrogen) binding to the gene termini:
Forward: 5’-GCGCGCGGATCCGTCAAAATGAAGACA 
ACCATTATT-3’
Reverse: 5’-GCGCGCCTCGAGAATTTAAATGCAAATG 
TTGCATCT-3’ 
PCR fragments were then digested with BglII and XhoI 
restriction enzymes and cloned into the pI.18 expression 
plasmid as used previously for other influenza HA pseudo-
types (Temperton et al, 2007). All plasmids were prepared 
and purified using kits from QIAGEN, according to the 
manufacturer’s instructions.
Influenza pseudotyped lentivirus particles expressing the 
firefly luciferase reporter gene were generated by plas-
mid co-transfection (Temperton et al, 2007; Figure 1). 
Approximately 4 × 106 human embryonic kidney 293T/17 
cells (American Type Cell Culture) were seeded into10 cm 
 diameter sterile, plastic dishes (Nunc) in DMEM medium 
with GlutaMAX and high glucose (Gibco, Invitrogen) plus 
10% (v/v) foetal bovine serum (Sigma) and 1% (v/v) peni-
cillin/streptomycin (Fisher) and placed at 37°C in a 5% 
CO
2
 (v/v) humidified incubator for 24 hrs. Next, the pI.18-
HA, gag/pol construct pCMV-D8.91 (Zufferey et al, 1997), 
 firefly luciferase construct pCSFLW (Wright et al, 2008) 
and pCAGGS-TMPRSS2 protease plasmids (Böttcher et al, 
2006) were combined and added to a Fugene6/OptiMEM 
medium mixture (Roche), and then to the cells according to 
the manufacturer’s instructions.
On the following day the medium was replaced and 1U of 
exogenous soluble Clostridium perfringens NA (Sigma) 
was added to facilitate sialic acid cleavage and pseudotype 
virus egress. Cell culture supernatant was harvested after 
further 24 hrs, passed through a 0.45 µm pore sterile syringe 
filter, aliquoted and stored at -80°C.
Titration of pseudotyped virus
Virus supernatant (5µl/well) was added to a 96-well plate 
along with 1 × 104 HEK293T target cells and 200 µl total 
medium per well and incubated as above for 48 hrs. Next, 
50 µl Bright-Glo luciferase reagent (Promega) was added, 
incubated for 5 min at room temperature and luminescence 
measured using a GloMax 96 luminometer and Relative 
Luminescence Units (RLU) per ml (auto-luminescence 
 normalised using cell only control) determined.
Pseudotype virus neutralization assay (PVNA)
PVNAs were performed using a standard protocol ( Temperton 
et al, 2007). Briefly, serially-diluted sera (1:40-1:200,000) 
were individually incubated with virus  supernatant (2.5 × 105 
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RLU per well, calculated from the titration result) for 1 hr 
at 37°C to permit antibody attachment to virus particles. 
Next, 1 × 104 cells were added to each well, incubated for 
48 hrs, and their luminescence read as described above. Test 
 sample results were normalised by deducting any back-
ground  luminescence produced by cell-only controls (no 
pseudotype virus). Additionally, the no-serum control (cells 
plus viruses) was included (equivalent to 0% neutralization). 
IC
50
 antibody titres (the reciprocal of the serum dilution 
 giving 50% inhibition of pseudotype virus entry) were calcu-
lated using  GraphPad Prism computer software. Values <80 
were considered negative (Katz et al, 1999; Garcia and Lai, 
2011).  Average values of two independent experiments are 
shown here. 
Single Radial Haemolysis (SRH) assay
The SRH assay was performed as described in the OIE 
(World Organisation for Animal Health) Terrestrial Manual 
(OIE, 2012) using A/equine/Sussex/89 (H3N8) as antigen.
RESULTS
Production of equine influenza pseudotyped virus using 
TMPRSS2
In order to generate infectious H3 subtype equine influenza 
pseudotyped virus (EIPV) particles, it was necessary to co-
transfect a plasmid expressing the TMPRSS2 endoprotease 
(transmembrane protease, serine S1 family member 2) to 
cleave the HA. No detectable virus was produced in the 
absence of this plasmid. The EIPV supernatant produced 
had a titre of 1 × 109 RLU/ml.
Measurement of neutralizing antibodies in equine sera 
using pseudotyped virus
The EIPV-containing supernatant produced was used to 
assay 20 equine serum samples (normalized data shown in 
Table 1). All samples from vaccinated animals exhibited 
IC
50
 antibody titres of >1100 and the positive control serum 
showed strong neutralization, with an IC
50
 of >40,000. The 
antibody titres of both serum samples from influenza-naïve 
animals were <80, the cut-off for a negative result.
Measurement of virus-specific antibodies by single 
radial haemolysis
Antibody was detected by SRH in the positive control serum 
and 18 of the 20 (90%) of the field sera. The SRH antibody 
levels ranged from 61-207 mm2 (Table 1).
Correlation of PVNA and SRH results
Data from the two assays was compared using GraphPad 
Prism software. Pearson analysis (assuming a normal/Gauss-
ian sample distribution) revealed a significant (p = 0.002) 
65% correlation (r value of 0.65) between the results.
DISCUSSION
Currently, the standard serological assays for animal and 
human influenza serology (e.g., assessment of vaccine 
efficacy and field epidemiology) are haemagglutination 
inhibition (HI), single radial haemolysis (SRH) and micro-
neutralization (MN). Although well established, they are 
often labour-intensive, suffer from consistency problems 
and use native pathogenic viruses, sometimes requiring 
Figure 1. Schematic of method for generation and titration of equine influenza HA pseudotyped lentivirus. Four plasmids  expressing 
the equine influenza virus (EIV) haemagglutinin (HA), HIV gag-pol, firefly luciferase reporter gene and TMPRSS2 protease are 
transfected into HEK293 cells. EIV pseudotyped lentivirus is harvested from virus supernatant, added to target 293 cells and relative 
transduction titre calculated from the level of reporter gene expression.
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tested whether this H3 subtype EIPV could be used to detect 
neutralizing antibodies in equines inoculated with a vaccine 
containing H3 subtype influenza viruses. Comparison was 
made to the established serological assay, SRH.
During natural infection, the newly synthesised influenza 
virus haemagglutinin protein (HA0) is cleaved by specific 
endoproteases into HA1 and HA2 subunits, to allow entry into 
 susceptible cells (reviewed in Steinhauer, 1999; Garten and 
Klenk, 2008). The HA1 mediates binding to the sialic acid 
receptor, while HA2 is involved in membrane fusion. A num-
ber of proteases have been implicated in this cleavage process. 
The HA0 of highly-pathogenic avian influenza (HPAI) viruses 
of the H5 and H7 subtypes (e.g., A/Viet Nam/1203/2004 
(H5N1)) have a polybasic cleavage site containing  multiple 
arginine and lysine residues that are cleaved by ubiquitous 
subtilisin-like endoproteases such as furin (reviewed in Stein-
hauer, 1999). All other influenza A viruses, including low path-
ogenicity avian influenza viruses, seasonal human  influenza 
and H3 equine influenza viruses, have monobasic cleavage 
sites with a single lysine or arginine residue ( Figure 2). It has 
been shown that cleavage at these sites is mediated by specific 
type II transmembrane serine proteases such as TMPRSS2 
and HAT (human airway trypsin-like protease) found in 
human airways (Böttcher et al, 2006; 2009). Consequently, we 
included a plasmid expressing the TMPRSS2 protease in the 
transfection procedure to mediate cleavage of the monobasic 
cleavage site in the equine pseudotype virus. By this approach, 
a high titre EIPV was successfully generated.
The pseudotype virus neutralization assay (PVNA) detected 
neutralizing antibodies in all of the sera from vaccinated 
equines and both negative controls had an IC
50
 of <80. 
There was general agreement between the antibody levels 
measured by PVNA and SRH, although two serum samples 
in which no antibodies were detected by SRH displayed a 
moderate neutralizing antibody level as measured by PVNA. 
Previous studies have shown good correlation between 
influenza-specific antibody titres in equine sera after  natural 
infection with influenza measured by SRH and virus neu-
tralisation assays (Morley et al, 1995), Furthermore, SRH 
antibody levels have been shown to correlate with pro-
tection after subsequent challenge (Mumford and Wood, 
1992). Though antibodies detected by SRH are largely 
neutralizing (Morley et al, 1995), there are differences 
between SRH and neutralization assays such as PVNA 
and  micro-neutralization (MN). For HA, SRH primar-
ily detects responses resulting from antibody interactions 
with the head of the trimer (though it does detect other 
viral  proteins), whereas both neutralization assays can also 
careful handling in containment facilities of biosafety level 
(BSL) 3 or above.
Retrovirus pseudotype technology has been used for diag-
nostic purposes and for basic research into a number of 
pathogenic RNA viruses that otherwise would have to be 
handled in BSL3/4 laboratories. These include Ebola virus 
(Wool-Lewis and Bates, 1998; Ito et al, 2001), hepatitis C 
(Bartosch et al, 2003; Hsu et al, 2003), SARS coronavirus 
(Nie et al, 2004; Temperton et al, 2005), rabies and lyssa-
viruses (Wright et al, 2008; 2009; 2010) as well as avian 
influenza viruses (Temperton et al, 2007). In contrast to the 
native viruses, their pseudotype counterparts can be handled 
in BSL1/2 facilities. 
In this ‘proof-of-principle’ study, we firstly aimed to pro-
duce a high-titre EIPV as a research tool. Secondly, we 
Figure 2. Alignment showing the monobasic cleavage site of the equine influenza virus strain used in the study, A/1/equine  Sussex/89 
(H3N8), compared with the same region of representative avian and human influenza strains. Note the polybasic cleavage site in 
A/Viet Nam/1203/2004 (H5N1) strain not present in the others. The red box indicates the conserved cleavage site region, with the 
 red-highlighted arginine (R) residue indicating the cleavage point. The green box shows the ‘fusion peptide’ allowing virus penetration 
of host cell endosomal membranes.
Table 1. Equine influenza H3N8 subtype-specific antibodies in 20 
equine sera as measured by pseudotype virus neutralization assay 
(PVNA) and single radial haemolysis (SRH). Shading used to 
 indicate relative antibody levels of response (SRH: d100 mm2 = light 
grey, 100-150 mm2 = medium grey, t150 mm2 = dark grey; PVNA: 
d5000 = light grey, d10000 = medium grey, t10000 = dark grey).
Serum sample PVNA (IC
50
) SRH (mm2)
1 1124 79
2 1860 0
3 4521 0
4 4627 83
5 4673 112
6 6136 118
7 6308 116
8 7500 100
9 7637 140
10 7863 61
11 8056 118
12 9179 118
13 9837 106
14 10523 58
15 11768 147
16 13237 153
17 17908 170
18 22843 207
19 35422 156
20 46617 181
Positive control 40824 136
Negative control 1 d80 d0.5
Negative control 2 d80 d0.5
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 efficiently detect responses to the HA stalk (Corti et al, 
2011). This may explain the two PVNA positive but SRH 
negative results. In a comparison of SRH, neutralization 
using swine embryo kidney (ESK) cells and HI tests using 
serum samples from horses that had received two doses of 
vaccine, Yamagishi et al (1982) found reasonable correla-
tion between the assays. The correlation between the SRH 
assay and the neutralisation test was 75% (r = 0.75). This is 
comparable to the 65% correlation (r = 0.65) seen between 
SRH and PVNA in the present study. Yamagishi et al also 
found that the SRH assay was less sensitive than both the 
HI and neutralisation tests. Our data similarly indicates the 
slightly greater sensitivity of a neutralization assay using 
pseudotype viruses compared with SRH.
The PVNA will be further developed by assessment of the 
sensitivity and specificity of the assay. We also intend to test 
the robustness and reproducibility of the assay by evaluating 
inter- and intra-laboratory variability. Finally, a protective 
titre will be determined using sera obtained from vaccina-
tion and challenge studies.
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